BioSpace News Archive

HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA”) non-bank custodian, today announced financial results for its third quarter ended October 31, 2019.

Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (“Allscripts”) today announced the commencement of a private offering of $200 million aggregate principal amount of its convertible senior notes due 2027 (the “notes”), subject to market and other conditions.

Deputy Chief Financial Officer of Aflac Incorporated Max K. Brodén will participate in a fireside chat at the Goldman Sachs U.S. Financial Services Conference 2019 on December 10, 2019 at 8:30 a.m. ET.

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 136,550 shares of Akebia’s common stock on November 29, 2019, as inducements material to each such employee’s entering into employment with Akebia.

LabCorp® announced the pricing terms of its previously announced cash tender offer for up to $300,000,000 principal amount of its outstanding $600,000,000 aggregate principal amount of 4.625% Senior Notes due 2020.

InfanDx has now initiated the quality-controlled data verification (close-out) for all 13 clinical sites in Germany and Turkey.

Creates Potential for Significantly Expanded Test Menu

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced that Siddharth Mittal has taken over as Chief Executive Officer & Joint Managing Director of the Company starting December 1, 2019. Mr. Mittal has been serving as Biocon’s Chief Financial Officer (CFO) since August 2014.

CASI Pharmaceuticals, Inc. announces that the China National Medical Product Administration, has approved the clinical trial applications for CNCT19 in relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma submitted by its partner Juventas Cell Therapy Ltd., a biopharmaceutical company focused on cell therapy.